Intel Veterans Raise $22M To Disrupt The Semiconductor Industry With The 'Baddest CPU In The World,' Backed By Apple And AMD Alum Jim Keller
Beaverton, Oregon-based semiconductor startup AheadComputing, founded by four former Intel (NASDAQ:INTC) central processing unit architects, announced in February that it secured $21.5 million in seed funding to develop a new class of high-performance processors based on the RISC-V architecture.
The seed funding round was led by Eclipse Ventures, with participation from Maverick Capital, Fundomo, and EPIQ Capital. The company also added Jim Keller to its board of directors. Keller is widely regarded as one of the foremost chip designers in the world, having held engineering leadership roles at Apple (NASDAQ:AAPL), Advanced Micro Devices (NASDAQ:AMD), Intel, and Tesla (NASDAQ:TSLA), The Oregonian reports.
Don't Miss:
Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —
Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can
The company, established in 2024, is aiming to design a scalable and power-efficient CPU that challenges x86 dominance in the data center and artificial intelligence sectors, The Oregonian says. Led by CEO Debbie Marr, AheadComputing intends to deliver what it calls the 'biggest, baddest CPU in the world.'
RISC-V, a royalty-free, open instruction set architecture, is emerging as a credible alternative to proprietary platforms such as Intel's x86 and ARM's licensed designs. According to The Oregonian, the architecture enables companies to create customized processors without licensing restrictions or vendor lock-in.
AheadComputing's team has grown to 80 employees, many of whom previously held senior roles at Intel. The company is targeting high-performance workloads in cloud infrastructure, AI inference, and edge computing applications. Its design leverages the modular 'chiplet' model, allowing for flexible system-on-chip configurations tailored to specific customer needs, The Oregonian reports.
Trending: Invest where it hurts — and help millions heal:.
Co-founder Jonathan Pearce told The Oregonian that the fragmentation of computing systems presents an opportunity for specialized vendors to offer optimized components within larger heterogeneous systems. 'You get the opportunity for a company like AheadComputing to provide that piece of the overall system. As opposed to the past 20 years where it was just one tech giant,' Pearce said.
AheadComputing operates as a fabless semiconductor company, outsourcing chip fabrication to partners such as Taiwan Semiconductor Manufacturing Co. This capital-efficient model allows the firm to focus resources on architectural innovation and design execution, The Oregonian reports.
Intel's long-standing position as Oregon's largest private employer is undergoing transition, with multiple senior engineers departing to build independent ventures. According to The Oregonian, AheadComputing represents one of the most ambitious spinouts, combining advanced design experience with startup agility.
Vice president of AheadComputing's design verification Alon Mahl said the hands-on startup environment allows engineering leaders to accelerate timelines and make immediate decisions without layers of corporate oversight. The Oregonian says that the team is already seeking larger office space in Washington County to accommodate growth and additional equipment needs.According to The Oregonian, AheadComputing joins a small group of Oregon-based chip startups led by Intel alumni, including Ampere Computing, which was recently acquired by SoftBank for $6.5 billion while retaining its Portland office footprint.
Portland State University professor Christof Teuscher, an expert in microprocessor architecture, said the startup is taking a high-risk, high-reward approach. While RISC-V has traditionally been used in academic and embedded contexts, The Oregonian says that Teuscher expressed skepticism about its ability to succeed in high-performance commercial environments.
According to The Oregonian, AheadComputing envisions its chips will eventually power PCs, laptops, and data centers, with possible clients including Google, Amazon (NASDAQ:AMZN), and Samsung.
Read Next:
Here's what Americans think you need to be considered wealthy.
Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to
Image: Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
APPLE (AAPL): Free Stock Analysis Report
TESLA (TSLA): Free Stock Analysis Report
This article Intel Veterans Raise $22M To Disrupt The Semiconductor Industry With The 'Baddest CPU In The World,' Backed By Apple And AMD Alum Jim Keller originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Cantor Fitzgerald Initiates Coverage on Docebo (DCBO) With an Overweight Rating
Docebo Inc. (NASDAQ:DCBO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, analyst Yi Fu Lee from Cantor Fitzgerald initiated coverage on Docebo Inc. (NASDAQ:DCBO) assigning an Overweight rating with a price target of $35 on the stock. This marks the first rating on the stock from Cantor Fitzgerald indicating firms' confidence in the company's potential and the overall industry condition. Docebo Inc. (NASDAQ:DCBO) is a leading learning platform that uses AI and innovation as its backbone. The company announced results for its fiscal first quarter of 2025 on March 9. The subscription revenue grew 13% year-over-year to $54.2 million, representing 95% of the total revenue. Whereas the total revenue also grew 11% year-over-year to $57.3 million. Notably, net income came in at $1.5 million. Both the revenue and EPS exceed market expectations, with revenue beating the consensus by $0.2 million and EPS topped by $0.05. A professional instructor delivering a customer education workshop. Management is anticipating second-quarter revenue between $59.0 million and $59.2 million. It expects subscription revenue to grow about 1.5% higher than overall company revenue. Docebo Inc. (NASDAQ:DCBO) provides an AI-powered learning platform that helps organizations create, manage, and deliver personalized training programs at scale. The company's platform enables organizations to deliver advanced learning experiences for its employees to drive measurable growth. While we acknowledge the potential of DCBO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
40 minutes ago
- Yahoo
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 11, analysts from Raymond James resumed coverage of Disc Medicine, Inc. (NASDAQ:IRON) with a strong Buy rating and a price target of $89. The resumed coverage comes as the company released its research note on Biotech names. The firm highlighted a favorable risk/reward profile in the biotech sector. It noted that while companies with a high probability of success for lead assets inspire higher conviction, investments in less de-risked assets like Disc Medicine, Inc. (NASDAQ:IRON) could yield the most outsized returns. The firm sees more than $1 billion potential for the company's drug bitopertin, with an expected market penetration of about 30%-35%, owing to its disease-modifying agent capabilities X-linked protoporphyria. A scientist in a laboratory setting examining a sample of blood with a microscope. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company focused on discovering therapies for serious hematologic diseases. Its pipeline includes drug candidates like bitopertin for erythropoietic porphyrias and Diamond-Blackfan Anemia, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera and other blood disorders. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
43 minutes ago
- Yahoo
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
